For instance, ACY-1215 (ricolinostat), a specific HDAC6 inhibitor, is undergoing a phase 1b trial for relapsed/refractory multiple myeloma, while ACY-241, a second-generation HDAC6 inhibitor with improved properties, is being investigated for multiple myeloma treatment. Here, HDAC6 is linked to plasma cell myeloma.